• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Halozyme Therapeutics Inc.

    5/13/25 11:18:25 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    HALOZYME THERAPEUTICS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    40637H109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    40637H109


    1Names of Reporting Persons

    STATE STREET CORPORATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,562,493.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,053,007.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,053,007.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    HALOZYME THERAPEUTICS INC
    (b)Address of issuer's principal executive offices:

    12390 EL CAMINO REAL , SAN DIEGO, CALIFORNIA, 92130
    Item 2. 
    (a)Name of person filing:

    STATE STREET CORPORATION;
    (b)Address or principal business office or, if none, residence:

    ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
    (c)Citizenship:

    MA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    40637H109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6053007.00
    (b)Percent of class:

    4.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    5,562,493

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    6,053,007

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    NOT APPLICABLE
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    NOT APPLICABLE

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STATE STREET CORPORATION
     
    Signature:ELIZABETH SCHAEFER
    Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
    Date:05/09/2025
    Get the next $HALO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    6/7/2024$48.00 → $51.00Overweight → Neutral
    Piper Sandler
    2/29/2024$54.00Outperform
    TD Cowen
    7/24/2023$61.00Buy
    H.C. Wainwright
    7/24/2023$43.00 → $45.00Buy → Neutral
    Goldman
    More analyst ratings

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

      SAN DIEGO, May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the

      5/5/25 5:15:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Halozyme Therapeutics Inc.

      SCHEDULE 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      5/13/25 11:18:25 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Halozyme Therapeutics Inc.

      10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:08:30 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:06:31 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

      SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      11/12/24 9:36:57 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Halozyme Therapeutics Inc.

      SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      10/17/24 9:36:19 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

      SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      2/13/24 5:06:13 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Posard Matthew L. was granted 4,165 shares, increasing direct ownership by 6% to 74,039 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:11:14 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miyashita Akiko Moni was granted 4,165 shares, increasing direct ownership by 20% to 24,937 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:09:44 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:08:05 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Financials

    Live finance-specific insights

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

      Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance  Reiterating 2025 Finan

      2/18/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Halozyme Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equal-Weight and set a new price target of $62.00

      5/14/25 8:56:30 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and set a new price target of $47.00

      5/13/25 8:55:01 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously

      10/7/24 8:32:56 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • Mahesh Krishnan Elected to Halozyme's Board of Directors

      SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.

      4/25/24 4:45:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Appoints Barbara Duncan to its Board of Directors

      SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan

      2/6/23 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care